| 000 | 01147 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250515193542.0 | ||
| 264 | 0 | _c20100205 | |
| 008 | 201002s 0 0 eng d | ||
| 022 | _a1879-0429 | ||
| 024 | 7 |
_a10.1016/j.copbio.2009.10.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStebbings, Richard | |
| 245 | 0 | 0 |
_aSafety of biologics, lessons learnt from TGN1412. _h[electronic resource] |
| 260 |
_bCurrent opinion in biotechnology _cDec 2009 |
||
| 300 |
_a673-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aClinical Trials, Phase I as Topic |
| 650 | 0 | 4 |
_aCytokines _xmetabolism |
| 650 | 0 | 4 |
_aDrug Evaluation, Preclinical _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xmethods |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 | _aSafety |
| 700 | 1 | _aPoole, Stephen | |
| 700 | 1 | _aThorpe, Robin | |
| 773 | 0 |
_tCurrent opinion in biotechnology _gvol. 20 _gno. 6 _gp. 673-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.copbio.2009.10.002 _zAvailable from publisher's website |
| 999 |
_c19280494 _d19280494 |
||